JAMES HEALY - 11 Jan 2022 Form 4 Insider Report for CinCor Pharma, Inc.

Role: Director, 10%+ Owner
Signature: /s/ Cathy Rude, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 11 Jan 2022
Net transactions value: +$5,200,000
Form type: 4
Filing time: 13 Jan 2022, 15:33:26 UTC
Previous filing: 11 Feb 2022
Next filing: 28 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CINC	Common Stock	Conversion of derivative security		+5,248,949			5,248,949	11 Jan 2022	By Sofinnova Venture Partners X, L.P.	F1, F2
transaction	CINC	Common Stock	Purchase	$5,200,000	+325,000	+6.2%	$16.00	5,573,949	11 Jan 2022	By Sofinnova Venture Partners X, L.P.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CINC	Series A Preferred Stock	Conversion of derivative security	$0	-13,571,428	-100%	$0.000000^*	0	11 Jan 2022	Common Stock	3,991,596		By Sofinnova Venture Partners X, L.P.	F1, F2
transaction	CINC	Series B Preferred Stock	Conversion of derivative security	$0	-4,275,000	-100%	$0.000000^*	0	11 Jan 2022	Common Stock	1,257,353		By Sofinnova Venture Partners X, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
F2	The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is a managing member of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

Content

Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.

The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is a managing member of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.